Prophylactic human papilloma virus vaccines for cervical cancer may also prevent development of breast and oropharyngeal cancers in women

Medical Hypotheses

Volumn 67, Issue 2, 2006, Pages 431-432

  Harputluoglu, Hakan ^a   Dizdar, Omer ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CELL IMMORTALIZATION; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LETTER; OROPHARYNX CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS INFECTION;

BREAST NEOPLASMS; FEMALE; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

HUMAN PAPILLOMAVIRUS;

EID: 33744757020     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.03.024     Document Type: Letter

References (3)

1. Cox J.T. The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?. Curr Opin Obstet Gynecol 18 Suppl. 1 (2006) s5-s13
2. Mayeaux Jr. E.J. Harnessing the power of prevention: human papillomavirus vaccines. Curr Opin Obstet Gynecol 18 Suppl. 1 (2006) s15-s21
3. Altundag O., Altundag K., Morandi P., and Gunduz M. Adjuvant targeted therapy with trastuzumab may decrease metastatic capacity in specific group of oropharyngeal cancer patients: downregulation of E-cadherin-catenin complex by cooperative effect of erbB-2 and human papilloma virus type 16 E6/E7 protooncogenes. Med Hypotheses 63 (2004) 277-280